首页 > 最新文献

International Journal of Bipolar Disorders最新文献

英文 中文
Prevention of suicidal behavior with lithium treatment in patients with recurrent mood disorders. 复发性情绪失调患者使用锂治疗预防自杀行为。
IF 4 2区 医学 Q2 PSYCHIATRY Pub Date : 2024-03-09 DOI: 10.1186/s40345-024-00326-x
Leonardo Tondo, Ross J Baldessarini

Suicidal behavior is more prevalent in bipolar disorders than in other psychiatric illnesses. In the last thirty years evidence has emerged to indicate that long-term treatment of bipolar disorder patients with lithium may reduce risk of suicide and attempts, with possibly similar benefits in recurrent major depressive disorder. We review and update selected research literature on effects of lithium treatment in reducing suicidal behavior and consider proposals that higher levels of lithium in drinking water may be associated with lower suicide rates. We summarize results of a growing number of randomized, controlled studies of lithium treatment for suicide prevention including comparisons with placebos or alternative treatments, and comment on the severe challenges of such trials. The basis of a proposed protective effect of lithium against suicidal behaviors remains uncertain but may include protective effects against recurrences of depressive phases of mood disorders, especially with mixed features or agitation, and possibly through beneficial effects on impulsivity, agitation and dysphoric mood.

与其他精神疾病相比,躁郁症患者的自杀行为更为普遍。在过去的三十年中,有证据表明,对双相情感障碍患者进行长期的锂治疗可以降低自杀和自杀未遂的风险,对复发性重度抑郁障碍患者也可能有类似的益处。我们回顾并更新了有关锂治疗对减少自杀行为影响的部分研究文献,并考虑了饮用水中锂含量越高,自杀率越低的建议。我们总结了越来越多关于锂治疗预防自杀的随机对照研究结果,包括与安慰剂或替代治疗的比较,并对此类试验所面临的严峻挑战进行了评论。锂对自杀行为的保护作用的基础仍不确定,但可能包括对情绪障碍抑郁阶段复发的保护作用,尤其是混合特征或激动,以及可能通过对冲动、激动和情绪不安的有益作用。
{"title":"Prevention of suicidal behavior with lithium treatment in patients with recurrent mood disorders.","authors":"Leonardo Tondo, Ross J Baldessarini","doi":"10.1186/s40345-024-00326-x","DOIUrl":"10.1186/s40345-024-00326-x","url":null,"abstract":"<p><p>Suicidal behavior is more prevalent in bipolar disorders than in other psychiatric illnesses. In the last thirty years evidence has emerged to indicate that long-term treatment of bipolar disorder patients with lithium may reduce risk of suicide and attempts, with possibly similar benefits in recurrent major depressive disorder. We review and update selected research literature on effects of lithium treatment in reducing suicidal behavior and consider proposals that higher levels of lithium in drinking water may be associated with lower suicide rates. We summarize results of a growing number of randomized, controlled studies of lithium treatment for suicide prevention including comparisons with placebos or alternative treatments, and comment on the severe challenges of such trials. The basis of a proposed protective effect of lithium against suicidal behaviors remains uncertain but may include protective effects against recurrences of depressive phases of mood disorders, especially with mixed features or agitation, and possibly through beneficial effects on impulsivity, agitation and dysphoric mood.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"12 1","pages":"6"},"PeriodicalIF":4.0,"publicationDate":"2024-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140068352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlations between multimodal neuroimaging and peripheral inflammation in different subtypes and mood states of bipolar disorder: a systematic review. 双相情感障碍不同亚型和情绪状态下多模态神经影像与外周炎症的相关性:系统性综述。
IF 4 2区 医学 Q2 PSYCHIATRY Pub Date : 2024-02-22 DOI: 10.1186/s40345-024-00327-w
Jing-Yi Long, Bo Li, Pei Ding, Hao Mei, Yi Li

Background: Systemic inflammation-immune dysregulation and brain abnormalities are believed to contribute to the pathogenesis of bipolar disorder (BD). However, the connections between peripheral inflammation and the brain, especially the interactions between different BD subtypes and episodes, remain to be elucidated. Therefore, we conducted the present study to provide a comprehensive understanding of the complex association between peripheral inflammation and neuroimaging findings in patients with bipolar spectrum disorders.

Methods: This systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42023447044) and conducted according to the Population, Intervention, Comparison, Outcomes, and Study Design (PICOS) framework. Online literature databases (PubMed, Web of Science, Scopus, EMBASE, MEDLINE, PsycINFO, and the Cochrane Library) were searched for studies that simultaneously investigated both peripheral inflammation-related factors and magnetic resonance neurography of BD patients up to July 01, 2023. Then, we analysed the correlations between peripheral inflammation and neuroimaging, as well as the variation trends and the shared and specific patterns of these correlations according to different clinical dimensions.

Results: In total, 34 publications ultimately met the inclusion criteria for this systematic review, with 2993 subjects included. Among all patterns of interaction between peripheral inflammation and neuroimaging, the most common pattern was a positive relationship between elevated inflammation levels and decreased neuroimaging measurements. The brain regions most susceptible to inflammatory activation were the anterior cingulate cortex, amygdala, prefrontal cortex, striatum, hippocampus, orbitofrontal cortex, parahippocampal gyrus, postcentral gyrus, and posterior cingulate cortex.

Limitations: The small sample size, insufficiently explicit categorization of BD subtypes and episodes, and heterogeneity of the research methods limited further implementation of quantitative data synthesis.

Conclusions: Disturbed interactions between peripheral inflammation and the brain play a critical role in BD, and these interactions exhibit certain commonalities and differences across various clinical dimensions of BD. Our study further confirmed that the fronto-limbic-striatal system may be the central neural substrate in BD patients.

背景:全身炎症-免疫失调和大脑异常被认为是双相情感障碍(BD)的发病机制。然而,外周炎症与大脑之间的联系,尤其是不同躁狂症亚型和发作之间的相互作用仍有待阐明。因此,我们开展了本研究,以全面了解双相情感谱系障碍患者的外周炎症与神经影像学发现之间的复杂关联:本系统综述在国际系统综述前瞻性注册数据库(PROSPERO)(CRD42023447044)中注册,并按照人群、干预、比较、结果和研究设计(PICOS)框架进行。我们在在线文献数据库(PubMed、Web of Science、Scopus、EMBASE、MEDLINE、PsycINFO 和 Cochrane Library)中搜索了截至 2023 年 7 月 1 日同时调查了 BD 患者外周炎症相关因素和磁共振神经影像学的研究。然后,我们分析了外周炎症与神经影像学之间的相关性,以及这些相关性根据不同临床维度的变化趋势、共同模式和特殊模式:最终共有 34 篇文献符合本系统综述的纳入标准,共纳入 2993 名受试者。在外周炎症与神经影像学之间的所有相互作用模式中,最常见的模式是炎症水平升高与神经影像学测量结果下降之间的正相关。最容易被炎症激活的脑区是扣带前皮层、杏仁核、前额叶皮层、纹状体、海马、眶额皮层、海马旁回、中央后回和扣带后皮层:局限性:样本量小、对BD亚型和发作的分类不够明确以及研究方法的异质性限制了定量数据综合的进一步实施:外周炎症与大脑之间的相互作用紊乱在BD中起着至关重要的作用,这些相互作用在BD的各种临床症状中表现出一定的共性和差异。我们的研究进一步证实,前边缘-纹状体系统可能是 BD 患者的中心神经基质。
{"title":"Correlations between multimodal neuroimaging and peripheral inflammation in different subtypes and mood states of bipolar disorder: a systematic review.","authors":"Jing-Yi Long, Bo Li, Pei Ding, Hao Mei, Yi Li","doi":"10.1186/s40345-024-00327-w","DOIUrl":"10.1186/s40345-024-00327-w","url":null,"abstract":"<p><strong>Background: </strong>Systemic inflammation-immune dysregulation and brain abnormalities are believed to contribute to the pathogenesis of bipolar disorder (BD). However, the connections between peripheral inflammation and the brain, especially the interactions between different BD subtypes and episodes, remain to be elucidated. Therefore, we conducted the present study to provide a comprehensive understanding of the complex association between peripheral inflammation and neuroimaging findings in patients with bipolar spectrum disorders.</p><p><strong>Methods: </strong>This systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42023447044) and conducted according to the Population, Intervention, Comparison, Outcomes, and Study Design (PICOS) framework. Online literature databases (PubMed, Web of Science, Scopus, EMBASE, MEDLINE, PsycINFO, and the Cochrane Library) were searched for studies that simultaneously investigated both peripheral inflammation-related factors and magnetic resonance neurography of BD patients up to July 01, 2023. Then, we analysed the correlations between peripheral inflammation and neuroimaging, as well as the variation trends and the shared and specific patterns of these correlations according to different clinical dimensions.</p><p><strong>Results: </strong>In total, 34 publications ultimately met the inclusion criteria for this systematic review, with 2993 subjects included. Among all patterns of interaction between peripheral inflammation and neuroimaging, the most common pattern was a positive relationship between elevated inflammation levels and decreased neuroimaging measurements. The brain regions most susceptible to inflammatory activation were the anterior cingulate cortex, amygdala, prefrontal cortex, striatum, hippocampus, orbitofrontal cortex, parahippocampal gyrus, postcentral gyrus, and posterior cingulate cortex.</p><p><strong>Limitations: </strong>The small sample size, insufficiently explicit categorization of BD subtypes and episodes, and heterogeneity of the research methods limited further implementation of quantitative data synthesis.</p><p><strong>Conclusions: </strong>Disturbed interactions between peripheral inflammation and the brain play a critical role in BD, and these interactions exhibit certain commonalities and differences across various clinical dimensions of BD. Our study further confirmed that the fronto-limbic-striatal system may be the central neural substrate in BD patients.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"12 1","pages":"5"},"PeriodicalIF":4.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10884387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139931058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lithium: how low can you go? 锂:你能降到多低?
IF 2.8 2区 医学 Q2 PSYCHIATRY Pub Date : 2024-01-30 DOI: 10.1186/s40345-024-00325-y
Rebecca Strawbridge, Allan H Young
{"title":"Lithium: how low can you go?","authors":"Rebecca Strawbridge, Allan H Young","doi":"10.1186/s40345-024-00325-y","DOIUrl":"10.1186/s40345-024-00325-y","url":null,"abstract":"","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"12 1","pages":"4"},"PeriodicalIF":2.8,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10828288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why is lithium [not] the drug of choice for bipolar disorder? a controversy between science and clinical practice. 为什么锂不是治疗躁郁症的首选药物?
IF 4 2区 医学 Q2 PSYCHIATRY Pub Date : 2024-01-16 DOI: 10.1186/s40345-023-00322-7
Lars Vedel Kessing

Background: During over half a century, science has shown that lithium is the most efficacious treatment for bipolar disorder but despite this, its prescription has consistently declined internationally during recent decades to approximately 35% ever use or less of patients with bipolar disorder.

Content: This narrative review provides an overview of the decreasing use of lithium in bipolar disorder internationally, shortly summarises the evidence for lithium's acute and prophylactic effects in bipolar disorder, discuss the challenges in relation to lithium including side effects, long-term risks and myths around lithium and provides two detailed examples on how specialised care models may result in successful increase of the use of lithium to 70% of patients with bipolar disorder largescale and improve care regionally and nationally.

Conclusions: Decades of scientific investigations and education and teaching of clinicians and the public has not increased the use of lithium on a population-based large scale. It is argued that lithium should be the drug of choice for maintenance therapy as the single first-line treatment and that organizational changes are needed with specialised care for bipolar disorder to systematically and long-term change the use of lithium on a large-scale population-level.

背景:半个多世纪以来,科学证明锂是治疗躁郁症最有效的药物,但尽管如此,近几十年来,国际上对锂的处方量持续下降,躁郁症患者对锂的使用率约为35%或更低:这篇叙述性综述概述了锂在躁郁症中的国际使用下降情况,简要总结了锂在躁郁症中的急性和预防性作用的证据,讨论了与锂有关的挑战,包括副作用、长期风险和与锂有关的神话,并提供了两个详细的例子,说明专业护理模式可如何成功地将锂的使用率大规模提高到 70%,并改善地区和国家的护理:结论:经过数十年的科学研究,以及对临床医生和公众的教育和培训,锂的使用并没有在人群中大规模增加。结论:数十年来的科学调查、教育和教学并没有增加锂盐在人群中的大规模使用,因此锂盐应该作为维持治疗的首选药物,并作为单一的一线治疗方法,同时需要对双相情感障碍的专业护理进行组织变革,以系统和长期地改变锂盐在人群中的大规模使用。
{"title":"Why is lithium [not] the drug of choice for bipolar disorder? a controversy between science and clinical practice.","authors":"Lars Vedel Kessing","doi":"10.1186/s40345-023-00322-7","DOIUrl":"10.1186/s40345-023-00322-7","url":null,"abstract":"<p><strong>Background: </strong>During over half a century, science has shown that lithium is the most efficacious treatment for bipolar disorder but despite this, its prescription has consistently declined internationally during recent decades to approximately 35% ever use or less of patients with bipolar disorder.</p><p><strong>Content: </strong>This narrative review provides an overview of the decreasing use of lithium in bipolar disorder internationally, shortly summarises the evidence for lithium's acute and prophylactic effects in bipolar disorder, discuss the challenges in relation to lithium including side effects, long-term risks and myths around lithium and provides two detailed examples on how specialised care models may result in successful increase of the use of lithium to 70% of patients with bipolar disorder largescale and improve care regionally and nationally.</p><p><strong>Conclusions: </strong>Decades of scientific investigations and education and teaching of clinicians and the public has not increased the use of lithium on a population-based large scale. It is argued that lithium should be the drug of choice for maintenance therapy as the single first-line treatment and that organizational changes are needed with specialised care for bipolar disorder to systematically and long-term change the use of lithium on a large-scale population-level.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"12 1","pages":"3"},"PeriodicalIF":4.0,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case-control study of patients with bipolar disorder and healthy control individuals. 神经变性生物标志物对认知功能的影响:一项对双相情感障碍患者和健康对照者进行的为期一年的纵向病例对照研究。
IF 4 2区 医学 Q2 PSYCHIATRY Pub Date : 2024-01-16 DOI: 10.1186/s40345-023-00324-5
Ulla Knorr, Anja Hviid Simonsen, Henrik Zetterberg, Kaj Blennow, Mira Willkan, Julie Forman, Kamilla Miskowiak, Steen Gregers Hasselbalch, Lars Vedel Kessing

Background: Abnormalities in cerebrospinal fluid (CSF)-amyloid-beta (Aβ)42, CSF-Aβ40, CSF-Aβ38, CSF-soluble amyloid precursor proteins α and β, CSF-total-tau, CSF-phosphorylated-tau, CSF-neurofilament light protein (NF-L), CSF-neurogranin, plasma-Aβ42, plasma-Aβ40, plasma-total-tau, plasma-NF-L and, serum-S100B during affective episodes may reflect brain changes that could impact cognitive function in patients with bipolar disorder (BD). The study aimed to investigate the association between these biomarkers indicative of Alzheimer's disease and those reflecting neurodegeneration alongside their impact on cognitive function in patients with BD and healthy control individuals (HC). The primary hypothesis was that GL and VL would increase with increasing levels of CSF-Aβ42 based on data from T0 and T3 in BD and HC jointly.

Methods: In a prospective, longitudinal case-control study euthymic patients with BD (N = 85) and HC (N = 44) were evaluated with clinical assessment and neuropsychological testing at baseline (T0) and during euthymia after a year (T3). Patients' affective states were recorded weekly as euthymic, subthreshold level, major depression, or (hypo)mania. If an episode occurred during follow-up, the patient was also assessed in post-episode euthymia. Cognitive performance was measured as a global cognitive score (GL) for four cognitive domains including verbal learning and memory (VL).

Results: Estimated in a linear mixed model GL increased with 0.001 for each increase of 1 pg/ml of CSF-Aβ42 (97.5%, CI 0.00043-0.0018, adjusted-p = 0.0005) while VL increased by 0.00089 (97.5%, CI 0.00015-0.0018, adjusted-p = 0.045) in BD and HC jointly. The association was weak, however stronger in patients with BD compared to HC. Associations between other biomarkers including CSF-neurogranin, and cognitive domains were overall weak, and none remained significant after adjustment for multiple testing.

Limitations: Modest sample size. A complete data set regarding both CSF-AB-42 and cognitive test scores was obtained from merely 61 patients with BD and 38 HC individuals.

Conclusion: CSF-Aβ42 may be associated with cognitive dysfunction in patients with BD and HC individuals. The association appeared to be stronger in BD but with overlapping confidence intervals. Hence it remains uncertain whether the association is a general phenomenon or driven by BD.

背景:脑脊液(CSF)-淀粉样β(Aβ)42、CSF-Aβ40、CSF-Aβ38、CSF-可溶性淀粉样前体蛋白α和β、CSF-总tau、CSF-磷酸化tau、CSF-神经丝蛋白(NF-L)异常、在情感发作期间,CSF-神经粒蛋白、血浆-Aβ42、血浆-Aβ40、血浆-总tau、血浆-NF-L和血清-S100B可能会反映大脑的变化,从而影响双相情感障碍(BD)患者的认知功能。该研究旨在调查这些指示阿尔茨海默病的生物标记物与反映神经变性的生物标记物之间的关联,以及它们对双相情感障碍患者和健康对照个体(HC)认知功能的影响。根据 BD 和 HC 的 T0 和 T3 数据,主要假设是 GL 和 VL 会随着 CSF-Aβ42 水平的增加而增加:方法:在一项前瞻性纵向病例对照研究中,在基线(T0)和一年后(T3)的亢进期,对 BD(85 人)和 HC(44 人)患者进行了临床评估和神经心理学测试。患者的情绪状态每周记录一次,分别记录为情绪稳定、亚阈值水平、重度抑郁或(低)躁狂。如果患者在随访期间病情发作,还将对其发作后的亢奋状态进行评估。认知表现以包括言语学习和记忆(VL)在内的四个认知领域的总体认知得分(GL)来衡量:在线性混合模型中估计,CSF-Aβ42每增加1 pg/ml,GL增加0.001(97.5%,CI 0.00043-0.0018,调整后p = 0.0005),而在BD和HC中,VL增加0.00089(97.5%,CI 0.00015-0.0018,调整后p = 0.045)。与 HC 相比,BD 患者的相关性较弱,但更强。其他生物标志物(包括CSF-神经粒腺苷)与认知领域之间的关联总体较弱,经多重测试调整后仍无显著关联:样本量有限。仅从61名BD患者和38名HC个体中获得了有关CSF-AB-42和认知测试得分的完整数据集:结论:CSF-Aβ42可能与BD患者和HC患者的认知功能障碍有关。BD患者的相关性似乎更强,但置信区间重叠。因此,目前仍无法确定这种关联是一种普遍现象还是由 BD 驱动的。
{"title":"Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case-control study of patients with bipolar disorder and healthy control individuals.","authors":"Ulla Knorr, Anja Hviid Simonsen, Henrik Zetterberg, Kaj Blennow, Mira Willkan, Julie Forman, Kamilla Miskowiak, Steen Gregers Hasselbalch, Lars Vedel Kessing","doi":"10.1186/s40345-023-00324-5","DOIUrl":"10.1186/s40345-023-00324-5","url":null,"abstract":"<p><strong>Background: </strong>Abnormalities in cerebrospinal fluid (CSF)-amyloid-beta (Aβ)42, CSF-Aβ40, CSF-Aβ38, CSF-soluble amyloid precursor proteins α and β, CSF-total-tau, CSF-phosphorylated-tau, CSF-neurofilament light protein (NF-L), CSF-neurogranin, plasma-Aβ42, plasma-Aβ40, plasma-total-tau, plasma-NF-L and, serum-S100B during affective episodes may reflect brain changes that could impact cognitive function in patients with bipolar disorder (BD). The study aimed to investigate the association between these biomarkers indicative of Alzheimer's disease and those reflecting neurodegeneration alongside their impact on cognitive function in patients with BD and healthy control individuals (HC). The primary hypothesis was that GL and VL would increase with increasing levels of CSF-Aβ42 based on data from T0 and T3 in BD and HC jointly.</p><p><strong>Methods: </strong>In a prospective, longitudinal case-control study euthymic patients with BD (N = 85) and HC (N = 44) were evaluated with clinical assessment and neuropsychological testing at baseline (T0) and during euthymia after a year (T3). Patients' affective states were recorded weekly as euthymic, subthreshold level, major depression, or (hypo)mania. If an episode occurred during follow-up, the patient was also assessed in post-episode euthymia. Cognitive performance was measured as a global cognitive score (GL) for four cognitive domains including verbal learning and memory (VL).</p><p><strong>Results: </strong>Estimated in a linear mixed model GL increased with 0.001 for each increase of 1 pg/ml of CSF-Aβ42 (97.5%, CI 0.00043-0.0018, adjusted-p = 0.0005) while VL increased by 0.00089 (97.5%, CI 0.00015-0.0018, adjusted-p = 0.045) in BD and HC jointly. The association was weak, however stronger in patients with BD compared to HC. Associations between other biomarkers including CSF-neurogranin, and cognitive domains were overall weak, and none remained significant after adjustment for multiple testing.</p><p><strong>Limitations: </strong>Modest sample size. A complete data set regarding both CSF-AB-42 and cognitive test scores was obtained from merely 61 patients with BD and 38 HC individuals.</p><p><strong>Conclusion: </strong>CSF-Aβ42 may be associated with cognitive dysfunction in patients with BD and HC individuals. The association appeared to be stronger in BD but with overlapping confidence intervals. Hence it remains uncertain whether the association is a general phenomenon or driven by BD.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"12 1","pages":"2"},"PeriodicalIF":4.0,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139471545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cognitive behavioural therapy for social anxiety disorder in people with bipolar disorder: a case series. 认知行为疗法治疗双相情感障碍患者的社交焦虑症:病例系列。
IF 4 2区 医学 Q2 PSYCHIATRY Pub Date : 2024-01-05 DOI: 10.1186/s40345-023-00321-8
Barbara Pavlova, Emma Warnock-Parkes, Martin Alda, Rudolf Uher, David M Clark

Background: Social anxiety disorder increases the likelihood of unfavourable outcomes in people with bipolar disorder. Cognitive behavioural therapy (CBT) is the first-line treatment for social anxiety disorder. However, people with bipolar disorder have been excluded from the studies that this recommendation is based on.  METHOD: We completed a case series to obtain initial data on whether CBT is an acceptable, safe, and effective treatment for social anxiety disorder in people with bipolar disorder.

Results: Eleven euthymic participants with bipolar disorder attended up to sixteen treatment and three follow-up sessions of CBT for social anxiety disorder. Participants attended on average 95% of the offered CBT sessions. No adverse events were reported. Participants' mean score on the Social Phobia Inventory decreased from 46.5 (SD 6.6) before the treatment to 19.8 (SD 11.9) at the end of the sixteen-session intervention and further to 15.8 (SD 10.3) by the end of the 3-month follow-up. This degree of improvement is equivalent to the effect observed in studies of CBT for social anxiety disorder in people without severe mental illness.

Conclusions: This case series provides preliminary evidence that CBT is acceptable, safe, and effective for treating social anxiety disorder in people with bipolar disorder during euthymia. A randomized controlled trial is needed to confirm these findings, and to establish whether treatment for social anxiety disorder improves the course of bipolar disorder.

背景:社交焦虑症会增加双相情感障碍患者出现不良后果的可能性。认知行为疗法(CBT)是治疗社交焦虑症的一线疗法。然而,这项建议所依据的研究并不包括双相情感障碍患者。 方法:我们完成了一项病例系列研究,以获得关于 CBT 是否是治疗双相情感障碍患者社交焦虑症的一种可接受、安全且有效的方法的初步数据:结果:11 名躁狂症患者参加了 16 次社交焦虑症 CBT 治疗和 3 次随访。参与者平均参加了95%的CBT疗程。无不良反应报告。参加者在社交恐惧症量表上的平均得分从治疗前的 46.5 分(标准差 6.6 分)降至 16 次干预结束时的 19.8 分(标准差 11.9 分),并在 3 个月的随访结束时进一步降至 15.8 分(标准差 10.3 分)。这种改善程度相当于对无严重精神疾病的社交焦虑症患者进行 CBT 治疗的效果:本系列病例提供了初步证据,证明 CBT 可以接受、安全且有效地治疗躁郁症患者的社交焦虑症。要证实这些研究结果,并确定社交焦虑症的治疗是否能改善双相情感障碍的病程,还需要进行随机对照试验。
{"title":"Cognitive behavioural therapy for social anxiety disorder in people with bipolar disorder: a case series.","authors":"Barbara Pavlova, Emma Warnock-Parkes, Martin Alda, Rudolf Uher, David M Clark","doi":"10.1186/s40345-023-00321-8","DOIUrl":"10.1186/s40345-023-00321-8","url":null,"abstract":"<p><strong>Background: </strong>Social anxiety disorder increases the likelihood of unfavourable outcomes in people with bipolar disorder. Cognitive behavioural therapy (CBT) is the first-line treatment for social anxiety disorder. However, people with bipolar disorder have been excluded from the studies that this recommendation is based on.  METHOD: We completed a case series to obtain initial data on whether CBT is an acceptable, safe, and effective treatment for social anxiety disorder in people with bipolar disorder.</p><p><strong>Results: </strong>Eleven euthymic participants with bipolar disorder attended up to sixteen treatment and three follow-up sessions of CBT for social anxiety disorder. Participants attended on average 95% of the offered CBT sessions. No adverse events were reported. Participants' mean score on the Social Phobia Inventory decreased from 46.5 (SD 6.6) before the treatment to 19.8 (SD 11.9) at the end of the sixteen-session intervention and further to 15.8 (SD 10.3) by the end of the 3-month follow-up. This degree of improvement is equivalent to the effect observed in studies of CBT for social anxiety disorder in people without severe mental illness.</p><p><strong>Conclusions: </strong>This case series provides preliminary evidence that CBT is acceptable, safe, and effective for treating social anxiety disorder in people with bipolar disorder during euthymia. A randomized controlled trial is needed to confirm these findings, and to establish whether treatment for social anxiety disorder improves the course of bipolar disorder.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"12 1","pages":"1"},"PeriodicalIF":4.0,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10769945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lithium prescription trends in psychiatric inpatient care 2014 to 2021: data from a Bavarian drug surveillance project 2014 年至 2021 年精神科住院病人的锂处方趋势:巴伐利亚药物监测项目提供的数据
IF 4 2区 医学 Q2 PSYCHIATRY Pub Date : 2023-12-19 DOI: 10.1186/s40345-023-00323-6
Paul Kriner, Emanuel Severus, Julie Korbmacher, Lisa Mußmann, Florian Seemueller
Lithium (Li) remains one of the most valuable treatment options for mood disorders. However, current knowledge about prescription practices in Germany is limited. The objective of this study is to estimate the prevalence of current Li use over time and in selected diagnoses, highlighting clinically relevant aspects such as prescription rates in elderly patients, concomitant medications, important drug–drug interactions, and serious adverse events. We conducted a descriptive analysis of Li prescriptions, analyzing data from the ongoing Bavarian multicenter drug safety project Pharmaco-Epidemiology and Vigilance (Pharmako-EpiVig) from the years 2014–2021. Our study included 97,422 inpatients, 4543 of whom were prescribed Li. The Li prescription rate in unipolar depression (UD) remained constant at 4.6% over the observational period. In bipolar disorder (BD), the prescription rate increased significantly from 28.8% in 2014 to 34.4% in 2019. Furthermore, 30.3% of patients with Li prescriptions did not have a diagnosis of BD or UD, and 15.3% of patients with schizoaffective disorder were prescribed Li. The majority (64%) of patients with Li prescriptions were prescribed five or more drugs. Most of the 178 high-priority drug–drug interactions were due to hydrochlorothiazide (N = 157) followed by olmesartan (N = 16). Our study does not substantiate concerns about a decline in Li prescription. The decline in prescription rates observed in some diagnostic groups in 2020 and 2021 may be associated with the COVID-19 pandemic. The symptom-oriented use of Li beyond BD and UD is common. Polypharmacy and drug–drug interactions present a challenge in Li therapy. Old age and comorbid substance use disorder do not appear to be major deterrents for clinicians to initiate Li therapy.
锂(Li)仍然是治疗情绪障碍最有价值的方法之一。然而,目前人们对德国的处方做法了解有限。本研究的目的是估算当前锂在不同时期和特定诊断中的使用率,重点关注与临床相关的方面,如老年患者的处方率、伴随用药、重要的药物相互作用和严重不良事件。我们对 Li 处方进行了描述性分析,分析了巴伐利亚多中心药物安全项目 "药物流行病学与警戒"(Pharmako-EpiVig)2014-2021 年的数据。我们的研究纳入了 97422 名住院患者,其中 4543 人被处方 Li。在观察期内,单相抑郁症(UD)的李处方率一直保持在 4.6%。在双相情感障碍(BD)中,处方率从2014年的28.8%大幅上升至2019年的34.4%。此外,30.3%的李处方患者未被诊断为双相情感障碍或躁狂症,15.3%的精神分裂症患者被处方李。大多数(64%)李处方患者被处方五种或五种以上药物。在 178 例高优先级药物相互作用中,大多数是氢氯噻嗪(157 例),其次是奥美沙坦(16 例)。我们的研究并未证实有关李氏处方减少的担忧。2020 年和 2021 年在某些诊断组别中观察到的处方率下降可能与 COVID-19 大流行有关。除 BD 和 UD 外,以症状为导向使用 Li 的情况也很常见。多重用药和药物间的相互作用给 Li 治疗带来了挑战。高龄和合并药物使用障碍似乎并不是阻碍临床医生启动 Li 治疗的主要因素。
{"title":"Lithium prescription trends in psychiatric inpatient care 2014 to 2021: data from a Bavarian drug surveillance project","authors":"Paul Kriner, Emanuel Severus, Julie Korbmacher, Lisa Mußmann, Florian Seemueller","doi":"10.1186/s40345-023-00323-6","DOIUrl":"https://doi.org/10.1186/s40345-023-00323-6","url":null,"abstract":"Lithium (Li) remains one of the most valuable treatment options for mood disorders. However, current knowledge about prescription practices in Germany is limited. The objective of this study is to estimate the prevalence of current Li use over time and in selected diagnoses, highlighting clinically relevant aspects such as prescription rates in elderly patients, concomitant medications, important drug–drug interactions, and serious adverse events. We conducted a descriptive analysis of Li prescriptions, analyzing data from the ongoing Bavarian multicenter drug safety project Pharmaco-Epidemiology and Vigilance (Pharmako-EpiVig) from the years 2014–2021. Our study included 97,422 inpatients, 4543 of whom were prescribed Li. The Li prescription rate in unipolar depression (UD) remained constant at 4.6% over the observational period. In bipolar disorder (BD), the prescription rate increased significantly from 28.8% in 2014 to 34.4% in 2019. Furthermore, 30.3% of patients with Li prescriptions did not have a diagnosis of BD or UD, and 15.3% of patients with schizoaffective disorder were prescribed Li. The majority (64%) of patients with Li prescriptions were prescribed five or more drugs. Most of the 178 high-priority drug–drug interactions were due to hydrochlorothiazide (N = 157) followed by olmesartan (N = 16). Our study does not substantiate concerns about a decline in Li prescription. The decline in prescription rates observed in some diagnostic groups in 2020 and 2021 may be associated with the COVID-19 pandemic. The symptom-oriented use of Li beyond BD and UD is common. Polypharmacy and drug–drug interactions present a challenge in Li therapy. Old age and comorbid substance use disorder do not appear to be major deterrents for clinicians to initiate Li therapy.","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"9 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138744942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lifetime risk of severe kidney disease in lithium-treated patients: a retrospective study 锂治疗患者终生罹患严重肾病的风险:一项回顾性研究
IF 4 2区 医学 Q2 PSYCHIATRY Pub Date : 2023-12-09 DOI: 10.1186/s40345-023-00319-2
Mihaela Golic, Harald Aiff, Per-Ola Attman, Bernd Ramsauer, Staffan Schön, Steinn Steingrimsson, Jan Svedlund
Lithium is an essential psychopharmaceutical, yet side effects and concerns about severe renal function impairment limit its usage. Our objectives were to quantify the occurrence of chronic kidney disease stage 4 or higher (CKD4 +) within a lithium-treated population, using age- and time-specific cumulative incidence and age-specific lifetime risk as measures of disease occurrence. Additionally, we aimed to investigate the association between the duration of lithium treatment and the risk of CKD4 + . We identified patients from the Sahlgrenska University Hospital’s laboratory database. We conducted a retrospective cohort study employing cumulative incidence functions that account for competing deaths to estimate cumulative and lifetime risk of CKD4 + . A subdistribution hazards model was employed to explore baseline covariates. For measuring the association between the duration of lithium treatment and CKD4 + occurrence, we used a matched 1:4 case–control study design and logistic regression. Considering a 90-year lifetime horizon, the lifetime risk of CKD4 + for patients initiating lithium treatment between ages 55 and 74 ranged from 13.9% to 18.6%. In contrast, the oldest patient group, those starting lithium at 75 years or older, had a lower lifetime risk of 5.4%. The 10-year cumulative risk for patients starting lithium between ages 18 and 54 was minimal, ranging from 0% to 0.7%. Pre-treatment creatinine level was a predictive factor, with a hazard ratio of 4.6 (95% CI 2.75–7.68) for values within the upper third of the reference range compared to the lower third. Moreover, twenty or more years of lithium exposure showed a strong association with an increased risk of CKD4 + compared to 1–5 years of lithium use, with an odds ratio of 6.14 (95% CI 2.65–14.26). The risk of CKD4 + among lithium-treated patients exhibited significant age-related differences. Patients under 55 years old had negligible 10-year risk, while the lifetime risk for those aged 75 and older was limited. Duration of lithium treatment, especially exceeding 20 years, emerged as a significant risk factor. For individual risk assessment and prediction, consideration of age, pre-treatment creatinine levels, and the chosen time horizon for prediction is essential.
锂是一种重要的精神药物,但副作用和对严重肾功能损害的担忧限制了它的使用。我们的目标是使用年龄和时间特异性累积发病率和年龄特异性终生风险作为疾病发生的衡量标准,量化锂治疗人群中慢性肾病 4 期或以上(CKD4 +)的发生率。此外,我们还旨在研究锂治疗持续时间与 CKD4 + 风险之间的关系。我们从 Sahlgrenska 大学医院的实验室数据库中确定了患者。我们进行了一项回顾性队列研究,利用考虑了竞争性死亡的累积发病率函数来估算 CKD4 + 的累积风险和终生风险。我们采用了子分布危险模型来探讨基线协变量。为了测量锂治疗持续时间与 CKD4 + 发生率之间的关系,我们采用了 1:4 配对病例对照研究设计和逻辑回归。考虑到90年的生命周期,55岁至74岁开始接受锂治疗的患者一生中发生CKD4+的风险从13.9%到18.6%不等。相比之下,年龄最大的一组患者,即 75 岁或以上开始锂治疗的患者,终生风险较低,仅为 5.4%。18至54岁开始服用锂剂的患者的10年累积风险很小,从0%到0.7%不等。治疗前的肌酐水平是一个预测因素,与低三分之一的肌酐水平相比,治疗前肌酐水平在参考范围上三分之一的危险比为4.6(95% CI 2.75-7.68)。此外,与使用锂1-5年相比,接触锂20年或更长时间与CKD4+风险增加有密切关系,其几率比为6.14(95% CI 2.65-14.26)。锂治疗患者的 CKD4 + 风险表现出明显的年龄差异。55 岁以下患者的 10 年风险可忽略不计,而 75 岁及以上患者的终生风险有限。锂治疗的持续时间,尤其是超过 20 年的时间,是一个重要的风险因素。对于个人风险评估和预测,考虑年龄、治疗前肌酐水平和所选的预测时间范围至关重要。
{"title":"Lifetime risk of severe kidney disease in lithium-treated patients: a retrospective study","authors":"Mihaela Golic, Harald Aiff, Per-Ola Attman, Bernd Ramsauer, Staffan Schön, Steinn Steingrimsson, Jan Svedlund","doi":"10.1186/s40345-023-00319-2","DOIUrl":"https://doi.org/10.1186/s40345-023-00319-2","url":null,"abstract":"Lithium is an essential psychopharmaceutical, yet side effects and concerns about severe renal function impairment limit its usage. Our objectives were to quantify the occurrence of chronic kidney disease stage 4 or higher (CKD4 +) within a lithium-treated population, using age- and time-specific cumulative incidence and age-specific lifetime risk as measures of disease occurrence. Additionally, we aimed to investigate the association between the duration of lithium treatment and the risk of CKD4 + . We identified patients from the Sahlgrenska University Hospital’s laboratory database. We conducted a retrospective cohort study employing cumulative incidence functions that account for competing deaths to estimate cumulative and lifetime risk of CKD4 + . A subdistribution hazards model was employed to explore baseline covariates. For measuring the association between the duration of lithium treatment and CKD4 + occurrence, we used a matched 1:4 case–control study design and logistic regression. Considering a 90-year lifetime horizon, the lifetime risk of CKD4 + for patients initiating lithium treatment between ages 55 and 74 ranged from 13.9% to 18.6%. In contrast, the oldest patient group, those starting lithium at 75 years or older, had a lower lifetime risk of 5.4%. The 10-year cumulative risk for patients starting lithium between ages 18 and 54 was minimal, ranging from 0% to 0.7%. Pre-treatment creatinine level was a predictive factor, with a hazard ratio of 4.6 (95% CI 2.75–7.68) for values within the upper third of the reference range compared to the lower third. Moreover, twenty or more years of lithium exposure showed a strong association with an increased risk of CKD4 + compared to 1–5 years of lithium use, with an odds ratio of 6.14 (95% CI 2.65–14.26). The risk of CKD4 + among lithium-treated patients exhibited significant age-related differences. Patients under 55 years old had negligible 10-year risk, while the lifetime risk for those aged 75 and older was limited. Duration of lithium treatment, especially exceeding 20 years, emerged as a significant risk factor. For individual risk assessment and prediction, consideration of age, pre-treatment creatinine levels, and the chosen time horizon for prediction is essential.","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"113 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138560865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with suicide attempts in the antecedent illness trajectory of bipolar disorder and schizophrenia 躁郁症和精神分裂症前疾病轨迹中与自杀未遂相关的因素
IF 4 2区 医学 Q2 PSYCHIATRY Pub Date : 2023-12-08 DOI: 10.1186/s40345-023-00318-3
Alessandro Miola, Manuel Gardea-Reséndez, Javier Ortiz-Orendain, Nicolas A. Nunez, Mete Ercis, Brandon J. Coombes, Manuel Fuentes Salgado, Peggy M. Gruhlke, Ian Michel, J. Michael Bostwick, Alastair J. McKean, Aysegul Ozerdem, Mark A. Frye
Factors associated with suicide attempts during the antecedent illness trajectory of bipolar disorder (BD) and schizophrenia (SZ) are poorly understood. Utilizing the Rochester Epidemiology Project, individuals born after 1985 in Olmsted County, MN, presented with first episode mania (FEM) or psychosis (FEP), subsequently diagnosed with BD or SZ were identified. Patient demographics, suicidal ideation with plan, self-harm, suicide attempts, psychiatric hospitalizations, substance use, and childhood adversities were quantified using the electronic health record. Analyses pooled BD and SZ groups with a transdiagnostic approach given the two diseases were not yet differentiated. Factors associated with suicide attempts were examined using bivariate methods and multivariable logistic regression modeling. A total of 205 individuals with FEM or FEP (BD = 74, SZ = 131) were included. Suicide attempts were identified in 39 (19%) patients. Those with suicide attempts during antecedent illness trajectory were more likely to be female, victims of domestic violence or bullying behavior, and have higher rates of psychiatric hospitalizations, suicidal ideation with plan and/or self-harm, as well as alcohol, drug, and nicotine use before FEM/FEP onset. Based on multivariable logistic regression, three factors remained independently associated with suicidal attempts: psychiatric hospitalization (OR = 5.84, 95% CI 2.09–16.33, p < 0.001), self-harm (OR = 3.46, 95% CI 1.29–9.30, p = 0.014), and nicotine use (OR = 3.02, 95% CI 1.17–7.76, p = 0.022). Suicidal attempts were prevalent during the antecedents of BD and SZ and were associated with several risk factors before FEM/FEP. Their clinical recognition could contribute to improve early prediction and prevention of suicide during the antecedent illness trajectory of BD and SZ.
人们对双相情感障碍(BD)和精神分裂症(SZ)前病程中自杀未遂的相关因素知之甚少。我们利用罗切斯特流行病学项目(Rochester Epidemiology Project),对明尼苏达州奥姆斯特德县 1985 年后出生、首次出现躁狂症(FEM)或精神病(FEP)、随后被诊断为躁狂症或精神分裂症的患者进行了鉴定。利用电子健康记录对患者的人口统计学特征、有计划的自杀意念、自残、自杀未遂、精神病住院、药物使用和童年逆境进行了量化。鉴于BD和SZ这两种疾病尚未区分开来,因此采用跨诊断方法对BD组和SZ组进行了汇总分析。采用双变量方法和多变量逻辑回归模型研究了与自杀未遂相关的因素。研究共纳入了 205 名 FEM 或 FEP 患者(BD = 74 人,SZ = 131 人)。其中有 39 名(19%)患者自杀未遂。在前疾病轨迹中自杀未遂的患者更有可能是女性、家庭暴力或欺凌行为的受害者,并且在FEM/FEP发病前有较高的精神病住院率、有计划的自杀意念和/或自残率,以及酒精、药物和尼古丁的使用率。根据多变量逻辑回归,有三个因素仍与自杀未遂行为独立相关:精神病住院(OR = 5.84,95% CI 2.09-16.33,p < 0.001)、自残(OR = 3.46,95% CI 1.29-9.30,p = 0.014)和使用尼古丁(OR = 3.02,95% CI 1.17-7.76,p = 0.022)。自杀企图在 BD 和 SZ 前驱期很普遍,与 FEM/FEP 前的几个风险因素有关。在 BD 和 SZ 的前疾病轨迹中,对这些自杀企图的临床识别有助于提高对自杀的早期预测和预防。
{"title":"Factors associated with suicide attempts in the antecedent illness trajectory of bipolar disorder and schizophrenia","authors":"Alessandro Miola, Manuel Gardea-Reséndez, Javier Ortiz-Orendain, Nicolas A. Nunez, Mete Ercis, Brandon J. Coombes, Manuel Fuentes Salgado, Peggy M. Gruhlke, Ian Michel, J. Michael Bostwick, Alastair J. McKean, Aysegul Ozerdem, Mark A. Frye","doi":"10.1186/s40345-023-00318-3","DOIUrl":"https://doi.org/10.1186/s40345-023-00318-3","url":null,"abstract":"Factors associated with suicide attempts during the antecedent illness trajectory of bipolar disorder (BD) and schizophrenia (SZ) are poorly understood. Utilizing the Rochester Epidemiology Project, individuals born after 1985 in Olmsted County, MN, presented with first episode mania (FEM) or psychosis (FEP), subsequently diagnosed with BD or SZ were identified. Patient demographics, suicidal ideation with plan, self-harm, suicide attempts, psychiatric hospitalizations, substance use, and childhood adversities were quantified using the electronic health record. Analyses pooled BD and SZ groups with a transdiagnostic approach given the two diseases were not yet differentiated. Factors associated with suicide attempts were examined using bivariate methods and multivariable logistic regression modeling. A total of 205 individuals with FEM or FEP (BD = 74, SZ = 131) were included. Suicide attempts were identified in 39 (19%) patients. Those with suicide attempts during antecedent illness trajectory were more likely to be female, victims of domestic violence or bullying behavior, and have higher rates of psychiatric hospitalizations, suicidal ideation with plan and/or self-harm, as well as alcohol, drug, and nicotine use before FEM/FEP onset. Based on multivariable logistic regression, three factors remained independently associated with suicidal attempts: psychiatric hospitalization (OR = 5.84, 95% CI 2.09–16.33, p < 0.001), self-harm (OR = 3.46, 95% CI 1.29–9.30, p = 0.014), and nicotine use (OR = 3.02, 95% CI 1.17–7.76, p = 0.022). Suicidal attempts were prevalent during the antecedents of BD and SZ and were associated with several risk factors before FEM/FEP. Their clinical recognition could contribute to improve early prediction and prevention of suicide during the antecedent illness trajectory of BD and SZ.","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"27 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138553772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Behavioral lateralization in bipolar disorders: a systematic review. 双相情感障碍的行为偏侧化:一项系统综述。
IF 4 2区 医学 Q2 PSYCHIATRY Pub Date : 2023-12-01 DOI: 10.1186/s40345-023-00320-9
Annakarina Mundorf, Jette Borawski, Sebastian Ocklenburg

Background: Bipolar disorder (BD) is often seen as a bridge between schizophrenia and depression in terms of symptomatology and etiology. Interestingly, hemispheric asymmetries as well as behavioral lateralization are shifted towards a tendency of left-side or mixed-side bias in schizophrenia whereas no shift is observed in subjects with depression. Given the role of BD with both, (hypo)manic and depressive episodes, investigating hemispheric asymmetries in subjects with BD is an interesting objective.

Method: A systematic review of studies including measures of behavioral lateralization in the form of handedness, footedness, eyedness, and language lateralization was performed resulting in 25 suitable studies.

Results: A broad variety of methods was used to assess behavioral lateralization, especially for eyedness, footedness, and language lateralization hindering the integration of results. Additionally, for hand preference, studies frequently used different cut-off scores and classification systems. Overall, studies do not support alteration in side preference in BD subjects. Studies focusing on differences in handedness demonstrate that subjects show equal rates of right- and non-right-handedness as the general population. Few studies focusing on manic episodes point towards increased left-side bias in ear and eye dominance, but the small sample sizes and conflicting results warrant further investigation.

Conclusion: The results reinforce that some disorders, such as BD, should not be treated as a homogenous group but sub-groups should be analyzed within the patient's population. Particularly, clinical implications resulting from neuroimaging studies highlight the need to study hemispheric asymmetries given that they may be important to consider for brain stimulation protocols.

背景:双相情感障碍(BD)在症状学和病因学方面常被视为精神分裂症和抑郁症之间的桥梁。有趣的是,精神分裂症患者的大脑半球不对称和行为侧化倾向于左侧或混合侧偏,而抑郁症患者则没有这种倾向。鉴于双相障碍在(轻度)躁狂和抑郁发作中的作用,研究双相障碍受试者的半球不对称是一个有趣的目标。方法:系统回顾了包括行为偏侧化的研究,包括利手性、脚性、眼睛和语言偏侧化的测量,得出了25项合适的研究。结果:我们使用了多种方法来评估行为侧化,特别是对于影响结果整合的眼睛、脚和语言侧化。此外,对于手偏好,研究经常使用不同的分界点和分类系统。总的来说,研究不支持双相障碍受试者侧偏好的改变。关注惯用手差异的研究表明,研究对象的右撇子和非右撇子比例与一般人群相同。很少有关于躁狂发作的研究指出耳朵和眼睛的左侧偏倚增加,但样本量小,结果矛盾,值得进一步调查。结论:结果强调,某些疾病,如双相障碍,不应作为一个同质组来治疗,而应在患者群体中进行亚组分析。特别是,神经影像学研究的临床意义强调了研究半球不对称的必要性,因为它们可能对脑刺激方案的考虑很重要。
{"title":"Behavioral lateralization in bipolar disorders: a systematic review.","authors":"Annakarina Mundorf, Jette Borawski, Sebastian Ocklenburg","doi":"10.1186/s40345-023-00320-9","DOIUrl":"10.1186/s40345-023-00320-9","url":null,"abstract":"<p><strong>Background: </strong>Bipolar disorder (BD) is often seen as a bridge between schizophrenia and depression in terms of symptomatology and etiology. Interestingly, hemispheric asymmetries as well as behavioral lateralization are shifted towards a tendency of left-side or mixed-side bias in schizophrenia whereas no shift is observed in subjects with depression. Given the role of BD with both, (hypo)manic and depressive episodes, investigating hemispheric asymmetries in subjects with BD is an interesting objective.</p><p><strong>Method: </strong>A systematic review of studies including measures of behavioral lateralization in the form of handedness, footedness, eyedness, and language lateralization was performed resulting in 25 suitable studies.</p><p><strong>Results: </strong>A broad variety of methods was used to assess behavioral lateralization, especially for eyedness, footedness, and language lateralization hindering the integration of results. Additionally, for hand preference, studies frequently used different cut-off scores and classification systems. Overall, studies do not support alteration in side preference in BD subjects. Studies focusing on differences in handedness demonstrate that subjects show equal rates of right- and non-right-handedness as the general population. Few studies focusing on manic episodes point towards increased left-side bias in ear and eye dominance, but the small sample sizes and conflicting results warrant further investigation.</p><p><strong>Conclusion: </strong>The results reinforce that some disorders, such as BD, should not be treated as a homogenous group but sub-groups should be analyzed within the patient's population. Particularly, clinical implications resulting from neuroimaging studies highlight the need to study hemispheric asymmetries given that they may be important to consider for brain stimulation protocols.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"11 1","pages":"37"},"PeriodicalIF":4.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138459786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Bipolar Disorders
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1